Assessment of response to therapy in advanced breast cancer.
about
Both gene expression for orotate phosphoribosyltransferase and its ratio to dihydropyrimidine dehydrogenase influence outcome following fluoropyrimidine-based chemotherapy for metastatic colorectal cancerEvidence for a schedule-dependent deleterious interaction between paclitaxel, vinblastine and cisplatin (PVC) in the treatment of advanced transitional cell carcinomaCHEK2 mutations affecting kinase activity together with mutations in TP53 indicate a functional pathway associated with resistance to epirubicin in primary breast cancerDiscovery of IL-18 as a novel secreted protein contributing to doxorubicin resistance by comparative secretome analysis of MCF-7 and MCF-7/DoxA feasibility study evaluating the functional diffusion map as a predictive imaging biomarker for detection of treatment response in a patient with metastatic prostate cancer to the boneHER-2, p53, p21 and hormonal receptors proteins expression as predictive factors of response and prognosis in locally advanced breast cancer treated with neoadjuvant docetaxel plus epirubicin combination.A randomised trial comparing combination chemotherapy using mitomycin C, mitozantrone and methotrexate (3M) with vincristine, anthracycline and cyclophosphamide (VAC) in advanced breast cancer.Low-dose mitomycin and weekly low-dose doxorubicin combination chemotherapy for patients with metastatic breast carcinoma previously treated with cyclophosphamide, methotrexate, and 5-fluorouracil.Five-day continuous-infusion vinblastine in the treatment of breast cancer.Adriamycin, dibromodulcitol, and mitomycin combination chemotherapy for patients with metastatic breast carcinoma previously treated with cyclophosphamide, methotrexate, 5-fluorouracil, vincristine, and prednisone.Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer.Molecular alterations in key-regulator genes among patients with T4 breast carcinoma.Tumour response interpretation with new tumour response criteria vs the World Health Organisation criteria in patients with bone-only metastatic breast cancer.Predictive and prognostic impact of TP53 mutations and MDM2 promoter genotype in primary breast cancer patients treated with epirubicin or paclitaxel.Effects on quality of life, anti-cancer responses, breast conserving surgery and survival with neoadjuvant docetaxel: a randomised study of sequential weekly versus three-weekly docetaxel following neoadjuvant doxorubicin and cyclophosphamide in womCancer Response Criteria and Bone Metastases: RECIST 1.1, MDA and PERCIST.Prevention of doxorubicin-induced alopecia by scalp cooling in patients with advanced breast cancer.Tamoxifen versus aminoglutethimide in advanced breast carcinoma: a randomized cross-over trial.Long-term clinical outcome of oestrogen receptor-positive operable primary breast cancer in older women: a large series from a single centreGlomeruloid microvascular proliferation is associated with lack of response to chemotherapy in breast cancerProgestins in breast cancer treatment. A review.Nestin expression associates with poor prognosis and triple negative phenotype in locally advanced (T4) breast cancerHigh dose, dose-intensive chemotherapy with doxorubicin and cyclophosphamide for the treatment of advanced breast cancerInterferon plus tamoxifen treatment for advanced breast cancer: in vivo biologic effects of two growth modulatorsMulticentre cross over study of aminoglutethimide and trilostane in advanced postmenopausal breast cancer.Endocrine and clinical consequences of combination tamoxifen-aminoglutethimide in postmenopausal breast cancer.Tumour ploidy, response and survival in patients receiving endocrine therapy for advanced breast cancer.A comparison of two doses of adriamycin in the primary chemotherapy of disseminated breast carcinoma.Oestrogen receptors and the response to endocrine therapy in advanced breast cancer.Serum sialyl transferase levels in patients with metastatic breast cancer treated by chemotherapyEndocrinological and clinical evaluation of two doses of formestane in advanced breast cancerThe relationship between an objective response to chemotherapy and survival in advanced colorectal cancer.Combination goserelin and tamoxifen therapy in premenopausal advanced breast cancer: a multicentre study by the ITMO group. Italian Trials in Medical OncologyMarkers of type I collagen degradation and synthesis in the monitoring of treatment response in bone metastases from breast carcinoma.Hormone replacement therapy as treatment of breast cancer--a phase II study of Org OD 14 (tibilone).Therapeutic effects of the aromatase inhibitor fadrozole hydrochloride in advanced breast cancer.Weekly doxorubicin and continuous infusional 5-fluorouracil for advanced breast cancer.Low expression levels of ATM may substitute for CHEK2 /TP53 mutations predicting resistance towards anthracycline and mitomycin chemotherapy in breast cancer.Reproducibility and clinical correlations of post-treatment changes on CT of prostate cancer bone metastases treated with chemotherapy.Long-term maintenance of prognostic value of survivin and its relationship with p53 in T4 breast cancer patients
P2860
Q24651163-CCA9FF7C-A941-4E18-94A6-566756ECD863Q28344992-9FBEA902-30BE-46ED-A61A-8F0950D9F46BQ28473504-B30DD46B-DF2D-4CB4-AF4F-B4FEF4502C97Q28477021-57A80506-F453-4EAC-9AE8-6DA2939936AEQ31140219-4D2EB9ED-2F0F-4FA7-BCC9-873ADE8311B8Q33275622-88EE4DC0-7944-48E9-9004-EB644F90B181Q33381648-5C500F2E-D64F-4749-A05E-0A964B3C7C86Q33451057-0C1B7285-B181-4479-904E-983799ABACE5Q33459615-B7ACAA0F-9DE3-4275-ACF6-43379A57226FQ33479497-709B1661-2231-4B09-BB46-62366C3EF357Q33488159-383376E6-825D-45E1-BC5C-A859A09F4553Q33671525-A96ABF97-51DD-4FE0-B692-B9E2D6B426B6Q33723692-2CFCAE14-360D-4D0E-9904-0C82178DD3CCQ33893910-F5ADD679-4637-4C41-9E65-7CAADBD4B44BQ33904763-B970CB24-A7DD-446F-913C-A045F889A816Q34023973-A59FD3C9-791C-40BE-A826-C78FA3FEF1F6Q34777361-62170819-C4DC-4758-A10E-30C7CD9FEC42Q34785202-40991CDA-E569-49B4-876E-0A3B953CE0ACQ35006855-E702FCB3-A2D3-4907-97BA-5C549195BB66Q35108398-0CE31CC8-2C5F-469A-94AE-FBD19C245CA0Q35651439-5A09CB7F-AD91-4BB4-AD95-13268341545EQ35771435-307F3563-E111-4064-B998-8F2559E2012BQ35976530-A0A11EEF-5D8D-4FE1-B16B-F936D874C7BEQ35977297-835AEC37-308F-4144-B5B8-9F4DE348C81FQ35977554-E23E4D6B-6C8E-4314-B6CA-E390A4D55FE2Q35991573-3B3903CA-F2FE-40D3-9DEF-9B47EB45339EQ35992384-E8F81E47-2DCB-46EC-A37F-AE0547CAAA4FQ36028306-D428C405-BF71-4BF2-8EAE-70A11CEF7738Q36042603-BE86DA47-9227-4764-949E-4BE7A85F6B45Q36046781-6A97CB25-DCA3-460C-B73B-E2B7697A07BFQ36079441-7C3064D2-F4A8-48C9-8558-7A5F8C82581CQ36079539-9A8396F6-2C53-4206-8269-C985B496063AQ36080911-E681B46A-11A0-4DBB-ACB1-6D1A3D44C41DQ36134836-496F90EB-47D5-4096-A79D-3083200381FAQ36134846-DECBDE6B-0C4A-4212-AC14-FA3630701D88Q36135060-A97B58FF-5EEB-4D65-AA06-7A6EFE27CDF3Q36136402-FD153A01-389E-4F85-A3E1-64447D019586Q36245541-56D80C4C-1455-4D44-865B-B8C37ABE042AQ36365411-E44D7678-1220-45E4-939D-E8F7E0AF6D64Q36375382-D44E6D7C-B698-4456-B40A-4A367E1A24AA
P2860
Assessment of response to therapy in advanced breast cancer.
description
1977 nî lūn-bûn
@nan
1977年の論文
@ja
1977年論文
@yue
1977年論文
@zh-hant
1977年論文
@zh-hk
1977年論文
@zh-mo
1977年論文
@zh-tw
1977年论文
@wuu
1977年论文
@zh
1977年论文
@zh-cn
name
Assessment of response to therapy in advanced breast cancer.
@ast
Assessment of response to therapy in advanced breast cancer.
@en
type
label
Assessment of response to therapy in advanced breast cancer.
@ast
Assessment of response to therapy in advanced breast cancer.
@en
prefLabel
Assessment of response to therapy in advanced breast cancer.
@ast
Assessment of response to therapy in advanced breast cancer.
@en
P2093
P356
P1476
Assessment of response to therapy in advanced breast cancer.
@en
P2093
P2888
P304
P356
10.1038/BJC.1977.42
P407
P577
1977-03-01T00:00:00Z
P5875
P6179
1030429832